Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?

Heralded as “one of the boldest claims for a new intervention” [1], the concept of the polypill was first introduced in 2003 by Professors Nicholas Wald and Malcolm Law [2]. Conceived as a pill containing 3 blood pressure–lowering drugs from various classes, aspirin, statin, and folic acid, the polypill w as designed for 2 population types: all individuals with established cardiovascular disease (CVD), and because the relative risk for cardiovascular (CV) events increases linearly with age, all individuals without CVD but older than age 55 years.
Source: CVD Prevention and Control - Category: Cardiology Authors: Tags: Viewpoint Source Type: research